Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818367 | 0.86 | CYP1A2 (0.39) | L3MBTL1EPHX2FAAHSELPDNM1 | |
| SCHEMBL25839149 | 0.84 | CYP1A2 (0.35) | L3MBTL1EPHX2SELPLPAR1TSHR | |
| SCHEMBL16405256 | 0.82 | CASP2 (0.60) | FAAHCASP2LPAR1DNM1NAAA | |
| SCHEMBL10124145 | 0.82 | L3MBTL1 (0.49) | L3MBTL1EPHX2FAAHSELPCASP2 | |
| SCHEMBL10051017 | 0.81 | CASP2 (0.65) | L3MBTL1EPHX2FAAHSELPCASP2 | |
| SCHEMBL11887039 | 0.81 | ALDH1A1 (0.46) | L3MBTL1EPHX2FAAHSELPCASP2 | |
| SCHEMBL22953541 | 0.78 | EPHX2 (0.59) | L3MBTL1EPHX2FAAHSELPCASP2 | |
| SCHEMBL19786737 | 0.76 | EPHX2 (0.66) | L3MBTL1EPHX2FAAHSELPCASP2 | |
| SCHEMBL19818157 | 0.75 | CASP2 (0.60) | L3MBTL1EPHX2FAAHSELPCASP2 | |
| SCHEMBL18516678 | 0.75 | CASP2 (0.55) | L3MBTL1EPHX2FAAHSELPCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | SCOTT, JOHN KIM, JR. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | TOP1, ALG1, GNE | L3MBTL1 4605/4885EPHX2 2514/4885FAAH 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.